Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Female
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Image Processing, Computer-Assisted
/ methods
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Organs at Risk
/ radiation effects
Parotid Gland
/ diagnostic imaging
Prognosis
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
/ methods
Radiotherapy, Intensity-Modulated
/ adverse effects
Retrospective Studies
Submandibular Gland
/ diagnostic imaging
Tomography, X-Ray Computed
/ methods
Xerostomia
/ diagnosis
Head and neck cancer
Machine learning
Radiation therapy
Radiomics
Xerostomia
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
29 Jul 2019
29 Jul 2019
Historique:
received:
02
11
2018
accepted:
17
07
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
10
1
2020
Statut:
epublish
Résumé
To analyze baseline CT/MR-based image features of salivary glands to predict radiation-induced xerostomia 3-months after head-and-neck cancer (HNC) radiotherapy. A retrospective analysis was performed on 266 HNC patients who were treated using radiotherapy at our institution between 2009 and 2018. CT and T1 post-contrast MR images along with NCI-CTCAE xerostomia grade (3-month follow-up) were prospectively collected at our institution. CT and MR images were registered on which parotid/submandibular glands were contoured. Image features were extracted for ipsilateral/contralateral parotid and submandibular glands relative to the location of the primary tumor. Dose-volume-histogram (DVH) parameters were also acquired. Features were pre-selected based on Spearman correlation before modelling by examining the correlation with xerostomia (p < 0.05). A shrinkage regression analysis of the pre-selected features was performed using LASSO. The internal validity of the variable selection was estimated by repeating the entire variable selection procedure using a leave-one-out-cross-validation. The most frequently selected variables were considered in the final model. A generalized linear regression with repeated ten-fold cross-validation was developed to predict radiation-induced xerostomia at 3-months after radiotherapy. This model was tested in an independent dataset (n = 50) of patients who were treated at the same institution in 2017-2018. We compared the prediction performances under eight conditions (DVH-only, CT-only, MR-only, CT + MR, DVH + CT, DVH + CT + MR, Clinical+CT + MR, and Clinical+DVH + CT + MR) using the area under the receiver operating characteristic curve (ROC-AUC). Among extracted features, 7 CT, 5 MR, and 2 DVH features were selected. The internal cohort (n = 216) ROC-AUC values for DVH, CT, MR, and Clinical+DVH + CT + MR features were 0.73 ± 0.01, 0.69 ± 0.01, 0.70 ± 0.01, and 0.79 ± 0.01, respectively. The validation cohort (n = 50) ROC-AUC values for DVH, CT, MR, and Clinical+DVH + CT + MR features were 0.63, 0.57, 0.66, and 0.68, respectively. The DVH-ROC was not significantly different than the CT-ROC (p = 0.8) or MR-ROC (p = 0.4). However, the CT + MR-ROC was significantly different than the CT-ROC (p = 0.03), but not the Clinical+DVH + CT + MR model (p = 0.5). Our results suggest that baseline CT and MR image features may reflect baseline salivary gland function and potential risk for radiation injury. The integration of baseline image features into prediction models has the potential to improve xerostomia risk stratification with the ultimate goal of truly personalized HNC radiotherapy.
Identifiants
pubmed: 31358029
doi: 10.1186/s13014-019-1339-4
pii: 10.1186/s13014-019-1339-4
pmc: PMC6664784
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Subventions
Organisme : American Society for Radiation Oncology
ID : ASTRO-AAPM Physics Resident Seed Grant
Organisme : Sidney Kimmel Comprehensive Cancer Center
ID : Radiation Oncology Discovery Grant
Organisme : Canon Medical Systems
ID : NA
Références
Radiother Oncol. 2001 Dec;61(3):271-4
pubmed: 11730996
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):659-64
pubmed: 15936542
J Public Health Dent. 2006 Spring;66(2):152-8
pubmed: 16711637
NMR Biomed. 2011 Jul;24(6):592-611
pubmed: 21538631
Med Image Anal. 2013 Feb;17(2):194-208
pubmed: 23265798
Radiother Oncol. 2013 Oct;109(1):159-64
pubmed: 23993399
Radiother Oncol. 2013 Dec;109(3):384-7
pubmed: 24183861
Ther Clin Risk Manag. 2015 Feb 04;11:171-88
pubmed: 25691810
Ann Intern Med. 2015 May 19;162(10):735-6
pubmed: 25984857
Periodontol 2000. 2016 Feb;70(1):11-25
pubmed: 26662479
Am J Surg Pathol. 1989 Oct;13(10):879-99
pubmed: 2675654
J Magn Reson Imaging. 2016 Aug;44(2):445-55
pubmed: 26778191
Rofo. 2016 Jul;188(7):652-61
pubmed: 27139177
Radiother Oncol. 2017 Feb;122(2):185-191
pubmed: 27459902
Oral Dis. 2017 Jan;23(1):84-90
pubmed: 27580143
Clin Cancer Res. 2016 Dec 1;22(23):5765-5771
pubmed: 27803067
Phys Med Biol. 2017 Feb 7;62(3):927-947
pubmed: 28074785
Med Phys. 2017 Mar;44(3):1050-1062
pubmed: 28112418
Artif Intell Med. 2017 Sep;81:41-53
pubmed: 28325604
Phys Med Biol. 2017 Aug 01;62(16):R179-R206
pubmed: 28657906
Oral Oncol. 2017 Aug;71:150-155
pubmed: 28688683
Radiother Oncol. 2017 Aug;124(2):256-262
pubmed: 28764926
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1101-1110
pubmed: 28939226
Phys Imaging Radiat Oncol. 2017 Jan;1:34-40
pubmed: 29057333
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Radiol Med. 2018 Jun;123(6):415-423
pubmed: 29368244
Br J Radiol. 2018 Jun;91(1086):20170498
pubmed: 29451412
Acta Oncol. 2018 Aug;57(8):1070-1074
pubmed: 29513054
Front Oncol. 2018 Mar 05;8:35
pubmed: 29556480
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):285-291
pubmed: 29726357
Diagn Interv Imaging. 2018 May;99(5):269-270
pubmed: 29751945
Phys Med. 2018 Jun;50:13-19
pubmed: 29891089
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1308-1318
pubmed: 29891201
Radiother Oncol. 2018 Sep;128(3):459-466
pubmed: 29958772
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1319-1329
pubmed: 30003997
Adv Radiat Oncol. 2017 Dec 07;3(3):346-355
pubmed: 30197940
Oral Oncol. 2018 Dec;87:111-116
pubmed: 30527225
Med Phys. 2019 Feb;46(2):857-867
pubmed: 30536442
Medicines (Basel). 2018 Dec 11;5(4):null
pubmed: 30544901
Med Phys. 2019 Feb;46(2):456-464
pubmed: 30548601
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Acta Radiol Diagn (Stockh). 1982;23(2):149-51
pubmed: 7090852
Acta Oncol. 1994;33(5):487-91
pubmed: 7917360
AJNR Am J Neuroradiol. 1997 May;18(5):951-8
pubmed: 9159376